Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Seeks To Buy Development, Marketing Rights For New Drugs (Japan)

This article was originally published in PharmAsia News

Executive Summary

Looking ahead to 2010, Takeda Pharmaceutical is counting the costs of developing a drug from scratch and looking to partner with other companies for compounds in at least five areas. President Yasuchika Hasegawa says many of its primary drugs face patent expirations, so the firm is looking to buy development and marketing rights for new drugs in areas where the firm's pipeline is lacking, in depression and schizophrenia and irritable bowel syndrome. One urgent quest of Takeda is to find outside sources for lipid-lowering agents since its own TAK-475 faces concerns about side affects. (Click here for more - may require subscription



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts